<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02542111</url>
  </required_header>
  <id_info>
    <org_study_id>V-GDP</org_study_id>
    <nct_id>NCT02542111</nct_id>
  </id_info>
  <brief_title>A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL</brief_title>
  <official_title>A Phase II Study of the Efficacy and Safety of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <brief_summary>
    <textblock>
      This study is to evaluate the efficacy and safety of Bortezomib plus GDP in the treatment of
      non-GCB DLBCL patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Every 2 cycles during treatment and then every 3 months for 2 years</time_frame>
    <description>28 days as one cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed using the CTCAE</measure>
    <time_frame>Days 1 of each course and 4-6 weeks after final treatment</time_frame>
    <description>28 days as one cycle</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>V-GDP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bortezomib 1.6 mg/m2/d iv d1 and d8 Gemcitabine 1000mg/m2/d iv d1 and d8 Dexamethasone 40mg/d iv d1-4 cisplatin 25 mg/m2 iv d2-4 Frequency every 28 days Total cycles 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib IV</description>
    <arm_group_label>V-GDP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine IV</description>
    <arm_group_label>V-GDP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone IV</description>
    <arm_group_label>V-GDP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin IV</description>
    <arm_group_label>V-GDP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven diffuse large B-cell lymphoma non-GCB subtype. Previously
             treated with 1, and only 1, chemotherapy regimen including an anthracycline and
             excluding cisplatin, cytarabine, bortezomib and gemcitabine. Relapse after CR, less
             than PR or PR to previous treatment.

          2. No history of stem cell transplantation, and no intention for stem cell
             transplantation.

          3. Age between 16-75.

          4. ECOG&lt;3.

          5. At least 1 measurable tumor mass.

          6. Minimum life expectancy of 3 months.

          7. Written informed consent.

          8. No uncontrolled CNS involvement by lymphoma:No CNS disease at time of relapse;CNS
             disease diagnosed at initial presentation allowed provided a complete response for CNS
             disease was achieved and maintained.

        Exclusion Criteria:

          1. Chemotherapy or large field radiotherapy within 3 weeks prior to entering the study.

          2. Clinically significant active infection.

          3. Impaired liver, renal or other organ function not caused by lymphoma, which will
             interfere with the treatment schedule.

          4. Any significant medical or psychiatric condition that might prevent the patient from
             complying with all study procedures.

          5. Subject has â‰¥grade 2 peripheral neuropathy or grade 1 with pain within 14 days before
             enrollment.

          6. Patients who are pregnant or breast-feeding.

          7. HIV infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weili Zhao, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weili Zhao, Prof</last_name>
    <phone>64370045</phone>
    <phone_ext>610707</phone_ext>
    <email>zhao.weili@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pengpeng XU, MD</last_name>
    <phone>64370045</phone>
    <phone_ext>610707</phone_ext>
    <email>xpproc@msn.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pengpeng XU, MD</last_name>
      <phone>64370045</phone>
      <phone_ext>610707</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2015</study_first_submitted>
  <study_first_submitted_qc>September 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Weili</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>diffuse large b-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

